Last week, the New York Times published a rapturous profile of a drug marketing company called Medvi, which the paper declared to be the first one-ish man venture on track to surpass one billion dollars in revenue while leaning almost exclusively on AI to build and scale the business. The news was immediately met with a wave of online backlash over both the framing of the NYT piece and the ethics of the company at the center of it — and the company’s official response raises more questions than it answers.
Medvi is a company that Futurism has been aware of for some time now. It effectively operates as a marketing wrapper for telehealth companies that prescribe and fulfill orders for GLP-1 agonists and other compounded drugs — and as we first reported all the way back in May 2025, Medvi has engaged in a range of dishonest marketing practices. It’s plastered its website with AI-deepfaked images of phony patients passed off as the real deal, flaunted media logos insinuating that it garnered editorial coverage from mainstream media outlets when it hadn’t, and featured the name and likeness of at least one medical practitioner who told us that in reality he had nothing to do with the company.
The NYT‘s profile either downplayed or omitted all of these glaring ethical red flags. The article also definitively stated that Medvi had ceased its practice of using AI-fabricated before-and-after client photos — a declaration that, as we pointed out in a follow-up, wasn’t true.
We weren’t the only ones with qualms. As folks from across the health, tech, and business worlds were quick to point out online, at the time the NYT article was published, Medvi was being marketed on social media by a trove of Meta accounts featuring clearly fake doctors. In fact, in February 2026, Medvi LLC was issued a warning from the Food and Drug Administration (FDA) pointing to multiple violations on a Medvi-branded site, Medvi.io. In that February warning, the FDA said that the site, Medvi.io, was misleading consumers by featuring images of Medvi-branded pill bottles and vials of injectables — Medvi isn’t actually the compounder of any drugs it sells, leaning instead on various pharmacies — and suggesting that certain drug compounds Medvi peddles are FDA-approved when they aren’t. Both the fake doctors on social media and the FDA warning went unmentioned in the NYT piece.
Yesterday, in response to public backlash and new reporting from outlets including Futurism, Techdirt, Business Insider, and the pharma-focused outlet Drug Discovery & Development, Medvi and its founder, 41-year-old Matthew Gallagher, issued a statement that it characterized as a “response to external speculation” about the company and its marketing practices.
The statement Medvi provided focuses heavily on the…
Source link
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We blogs.grocliq.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at [email protected]
